Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 270 No 7250 p709-713
24 May 2003

News summary

DIARY   Branch meetings   Future Events   Conferences

709 Omeprazole to be a pharmacy medicine Galpharm Healthcare is seeking pharmacy medicine classification for omeprazole 10mg gastroresistant tablets. The company wants to market the product for the relief of heartburn (reflux-like symptoms) in adults ...[more]

709 Nottingham best for pharmacy: Guardian Nottingham University's school of pharmacy is the best place in Britain to study pharmacy, according to the Guardian's latest university guide...[more]

709 Pharmacy must not subsidise NHS Primary care trusts must not be allowed to use community pharmacy as a means of subsidising National Health Service building developments, the National Pharmaceutical Association says...[more]

709 "Flawed" study reignites MMR safety row The debate over the safety of the mumps, measles and rubella vaccine (MMR) vaccine has been reignited following the publication of a study questioning the vaccine's safety. But the Department of Health has dismissed the study as flawed...[more]

710 Evidence for pimecrolimus questioned and advertisement criticised by DTB No convincing evidence exists to justify the use of pimecrolimus (Elidel) cream in first-line management of atopic dermatitis, according to the Drug and Therapeutics Bulletin...[more]

710 PSNC concerned about lack of further Charter talks The Pharmaceutical Services Negotiating Committee has expressed concern at being told that there will not be a further round of consultation on the Royal Pharmaceutical Society's proposed new Charter...[more]

710 Keep lobbying MPs, NPA urges members Community pharmacists in England should continue to lobby Members of Parliament over control of entry, the National Pharmaceutical Association says...[more]

710 Scottish health minister...[more]

711 BP higher in Europe than in America Average blood pressure (BP) levels are higher in European countries, including England, than they are in North America, according to a review of eight national surveys...[more]

711 Low-dose diuretics still the best antihypertensives Low-dose diuretics are still the best first-line antihypertensives for preventing cardiovascular disease and deaths, according to a network meta-analysis...[more]

711 Combine drugs for high cholesterol Treatment with both atorvastatin (Lipitor) and ezetimibe (Ezetrol) is significantly better in reducing cholesterol levels than either alone, researchers say...[more]

ATS conference logoAmerican Thoracic Society conference 2003

711 Benefit of linezolid Patients given the oxazolidinone antibacterial linezolid (Zyvox) for methicillin resistant Staphylococcus aureus (MRSA) hospital acquired (nosocomial) pneumonia are more likely to survive than patients treated with vancomycin, according to a study presented this week at the American Thoracic Society conference in Seattle...[more]


712 More than 617 million prescriptions were dispensed in England last year More than 617 million prescriptions for medicines worth over £6.8bn were dispensed in England in 2002, according to detailed statistics issued by the Department of Health...[more]

712 Few Americans buy medicines on the internet Only five per cent of American internet users have obtained medicines from online pharmacies, according to a survey...[more]

713 Passive smoking risk might have been overstated, study suggests Passive smoking might not be as harmful as previously thought, research suggests...[more]

713 Second mode of action suggested for trilostane in breast cancer Clarification of the modes of action of trilostane (Modrenal) in breast cancer was given this week...[more]

713 Combination for osteoporosis...[more]

713 Anticonvulsant role in nausea...[more]

713 Patients want more information...[more]

713 Stepping down inhaled steroids...[more]

713 Guidance on anti-obesity drugs...[more]

Back to Top

  * PDF files on PJ Online require Acrobat Reader 4 or later.


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal